Introduction
Hospital-acquired hepatitis B virus (HBV) infection has been well described and continues to occur worldwide [1] [2] [3] [4] . Nosocomial HBV infection has traditionally been associated with the transfusion of contaminated blood and blood products. From the mid-1980s donor-screening programmes and testing of all donated blood has led to a dramatic decrease in transfusion-associated HBV infections [1] [2] . Nosocomial outbreaks have been linked to unsafe injection practices, use of multi-dose vials, and poor staff compliance with standard precautions including hand washing [1, 2, 5] .
Multiple HBV outbreaks have been reported in paediatric oncology inpatient settings [2, [6] [7] [8] . The increased risk of HBV infection in these patients may be attributed to a multitude of factors, including immunodeficiency caused by the underlying malignancy and cytostatic chemotherapy [2, 9] . Long-term admissions, because of prolonged treatment plans and travel restrictions, as well as poor HBV immunity, are also found in South Africa [6, 10] . Although the Expanded Programme on Immunisation in South Africa (EPI-SA) schedules HBV vaccinations during infancy, recent data suggest that children in haematology and oncology units have no or very low anti-HBV antibody titres [10] .
This article describes a nosocomial outbreak that occurred in a paediatric haematology and oncology unit of a large academic hospital, the epidemiological investigation of this outbreak, and preventive measures implemented to limit further in-hospital transmission. These measures include strict enforcement of standard precautions of infection control and the implementation of an immunisation programme for all patients admitted into the unit.
Materials and methods

Patients
The study included patients treated in the paediatric haematology and oncology unit The first three cases of HBV infection that initiated the outbreak investigation were diagnosed over a 50-day period (March to April 2012). They were asymptomatic and presented with deranged liver enzymes on routine blood monitoring. All these patients had tested negative for HBsAg and anti-HBc on first admission to the unit.
Outbreak investigation including contact tracing and HBV screening were initially carried out on all patients seen in the outpatient clinic and those admitted to the unit during the same period as the infected patients. During this first screening period 
Serological testing
All HBV serological testing was performed using Architect Immunoassays (Abbott Diagnostics, Sligo, Republic of Ireland). HBV viral load testing was performed using the Cobas AmpliPrep/Cobas TaqMan HBV Test v2.0 (Roche Molecular Systems, Inc., Branchburg, NJ).
Phylogenetic analysis
Viral nucleic acid was extracted from 1000µl of plasma using the MagNa Pure LC Total Nucleic Acid Isolation kit in the MagNa Pure LC instrument (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions.
HBV preC/C primers were used for nested HBV-PCR as previously described [11] .
Sequencing was performed at Inqaba Biotechnical company using published preC/C primers and method [12] .
Epidemiological investigation
All the medical information of the patients involved in the outbreak was gathered, including primary diagnosis, HIV status, outcome, as well as the serological markers of HBV infection.
Preventive measures
In response to the outbreak, all personnel working in the unit were re-educated about HBV transmission routes. The use of standard precautions including routine handwashing, usage of gloves, application of alcohol-containing hand spray, and appropriate waste disposal were reinforced. The practice of using multi-dose vials was abandoned.
Patients receiving treatment and the long-term follow-up patients who did not have sufficient immunity against HBV were given a hepatitis B vaccine booster dose, Heberbiovac HB (Centre for Genetic Engineering and Biotechnology, Havana, Cuba). We regard anti-HBs levels >100 mIU/mL as protective in our unit. This is based on previous reports which suggested that low immunity with anti-HBs levels between 10 and 100 mIU/mL, especially in immune compromised individuals, was not regarded as sufficiently protective [13] [14] [15] . Boosting of low levels of HBV immunity (10-100 mIU/mL) then became standard of care in patients. A full vaccination schedule (0, 1, 2, 6 months) is now given to patients with anti-HBs levels of <10 mIU/mL, and a single booster vaccine to patients with anti-HBs levels of 10-100 mIU/mL.
Results
Patient characteristics
During the outbreak investigation and the subsequent routine HBV screening in the unit, 408 patients have been tested for HBV. Forty-nine cases of HBV infection were confirmed from July 2011 to October 2013. Table I shows the timeline of events and the actions taken at each time point. Patient characteristics are summarized in Table   II . There were 30 boys and 19 girls with confirmed HBV infection, and the median age of the group was 10.8 years (range 2.0 to 20.5 years). Most of the patients (67.3%) were patients diagnosed with haematological malignancies, predominantly acute lymphoblastic leukaemia (19 of the 49 patients). Serum bilirubin and alanine transferase (ALT) levels were raised in seven asymptomatic infected patients, with serum bilirubin levels up to 35 μmol/L and serum ALT levels ranging from 46 to 1131 U/L. However, these abnormal results were not regarded as a reliable indicator of HBV-related liver damage in a setting where administration of cytotoxic chemotherapy often leads to similar biochemical abnormalities [2] . Forty of the fortynine (82%) HBV positive patients were undergoing chemotherapy. 
Serological markers
Initial HBV screening data were not available for 10 of the 49 infected patients. Only four patients had evidence of sufficient immunity on first contact to the unit, with antiHBs levels >100 mIU/mL. (Serological profiles are summarised in Table III. ) Thirtythree (67%) patients were HBeAg positive. The HBV viral load, available for 31 patients had a mean of 68,739,713 IU/mL, with a range of <50 IU/mL to ≥170,000,000 IU/mL. 
Phylogenetic analysis
Phylogenetic analysis was done on eight samples from seven patients. Analysis of the HBV preC/C gene nucleotide sequences revealed that all the outbreak strains clustered together (99% bootstrap value) and all belonged to genotype E (Figure 1 ).
Epidemiological investigation
All medical personnel involved in patient care in the unit were tested for HBsAg and they were advised to seek medical attention and were re-immunised if needed. We were unfortunately unable to access information on the screening of health care
workers as a result of patient confidentiality.
All blood products are supplied by the South African National Blood Service 
Influence of preventive measures
Measures to prevent further HBV infections were introduced following the outbreak.
A HBV re-vaccination programme was introduced for all patients without adequate immunity (anti-HBs <100 mIU/mL). 
Patient outcomes
Excluding the patient with acute HBV infection mentioned in the previous paragraph, 20 of the 48 (42%) patients were chronic carriers, 18 (38%) patients cleared HBV infection, two were lost to follow up and eight (17%) patients died from underlying unrelated medical conditions. Two patients were diagnosed and treated for acute liver failure related to HBV infection. In both these patients the liver function improved, although one of them subsequently died from progression of the primary disease (osteosarcoma).
Discussion
An unusually high number of HBV infections were recorded in a paediatric haematology and oncology unit during the time period July 2011 to October 2013.
Preventive measures were implemented to limit further in-hospital transmission of HBV.
There have been multiple reports of HBV outbreaks in paediatric oncology units worldwide [2, [6] [7] [8] . In our literature search the last reported outbreak in a South
African unit occurred over a period of 11 years (1983 to 1994) and included 61 patients [7] . Willers et al reported on paediatric patients that developed active hepatitis B infection during the course of oncology treatment in a South African unit (1998-1999), but did not conduct formal outbreak investigation or phylogenetic studies on samples of these patients [6] .
The majority of the patients (67%) that developed active HBV infection during the described outbreak were patients with haematological malignancies. Possible factors that might predispose this group of patients to develop HBV infection includes:
severe immune-suppression secondary to the disease, prolonged hospital admission, repeated venepunctures and an increased need for invasive procedures [6, 9] . Büchner et al reported on HBV immunity in this group of patients on first admission to the unit, and found a very low rate of sufficient anti-HB levels [10] .
Waning of immunity to HBV vaccination is well described in the literature [18, 19] . In children without chronic disease the immune memory has been shown to be well preserved despite the waning in anti-HBs titers. However, it has been shown even in a group of well children that this waning of HBV immunity places them at risk for breakthrough infection with HBV 10 to 15 years later [18] . Booster dose(s) may be needed in later childhood or early adolescence to provide continuous protection against HBV infection. [19] The male:female ratio of patients that acquired HBV was consistent with the patient population treated in the unit, therefore gender did not seem to be a predisposing factor. According to the South African National HIV Survey of 2012, HIV prevalence in children 0-19 years ranges from 0.7% to 5.6% [20] . The higher proportion of HIVinfected patients in this outbreak (8%) when compared to the national prevalence is in keeping with the known increased risk in HIV-infected patients of developing certain HIV-associated malignancies [21] . The majority (80%) of the patients described in the outbreak had subclinical HBV infection, which is in accordance with previous reports [6, 8, 9] .
HBeAg is an indicator of highly replicating hepatitis B virus and its presence indicates a high risk of infectivity. The rate of HBe-antigenaemia in this population (67%) is much higher than the 26% previously reported in African primary school children [22] . This higher rate is likely to be on account of immunosuppression. The high levels of HBV DNA in saliva, previously reported in children with HBeantigenaemia, support the hypothesis that saliva is a possible vehicle for horizontal transmission of HBV among children [3, 23] .
Nucleotide sequencing and phylogenetic analysis is currently the gold standard for tracing the origin of large outbreaks [2, 4, 8] . Eight genotypes of HBV (A-H) are recognised and have a specific geographic distribution [22] . We had access to limited phylogenetic analysis. In contrast to the predominant genotype A found in southern, eastern and central Africa, the phylogenetic analysis done on samples in this outbreak revealed genotype E, which is the most prevalent genotype of western and central Africa [22] , Outbreak investigations were further limited by a lack of initial serological data of 10/49 patients, one of which could have been the index patient.
Health care workers have been known to transmit HBV infection [24] [25] [26] . Testing for and management of HBV infection in health care workers is an important part of outbreak investigation [5, 27] . We were unable to access information on the screening of health care workers as a result of patient confidentiality. Future screening and vaccination of health care workers should be a transparent process and form part of standard protocol in haematology and oncology units. Despite being vaccinated as part of the EPI-SA programme, a significant proportion of patients attending the unit do not have sufficient protective antibodies against HBV at first presentation [10] . The lack of adequate or successful immunity response is a concern and will need further evaluation on local and programmatic levels. These patients are at risk of acquiring HBV infection in an environment where they may come in contact with highly infectious carriers. All haematology and oncology patients need to be screened for HBV at the first visit and regularly during the course of their treatment and follow up. Preventive measures should be described in a protocol, and include immunisation of all seronegative patients against HBV.
Implementation of an effective screening and vaccination programme in the oncology unit should protect these vulnerable patients from contracting HBV.
The use of combined passive-active immunisation should be encouraged, especially in children with haematological malignancies and HIV-infected children where a poor vaccine response is expected [29, 30] . The use of intravenous specific immune globulin containing high titre of anti-HBs (HBIG) in combination with HBV vaccination in children with malignant diseases has been studied in Poland [29] and India [30] . In both these studies this strategy offered better protection against nosocomial HBV infection than active immunisation alone. The cost implication of offering solely passive prophylaxis during intensive chemotherapy of patients with leukaemia and non-Hodgkin lymphoma led to this protocol being discontinued [29] .
Of the HBV-infected children described in this outbreak, 41% (20/49) were chronic carriers (HBsAg positive for >6 months). The rate of chronic carrier state that was found is similar to a published report by Sevinir et al [9] . Patients with chronic HBV infection have an increased risk of developing cirrhosis and hepatocellular carcinoma [9, 22, 23] . The complications of chronic hepatitis could have a detrimental effect on the long-term morbidity of this group of patients, which we are following up closely.
